The new corporate headquarters feature expansive modern offices and meeting rooms, R&D, manufacturing, packaging and shipping facilities, and cleanroom laboratories that are currently undergoing class 100 enhancements and certification for Clinical Laboratories Improvement Amendments (CLIA) and International Organization for Standardization (ISO) 9001 and 13485.

Arrayit develops, manufactures, markets, sells and supports patented and proprietary microarray products and services for university laboratories, government agencies, and life sciences, biotechnology, diagnostics and pharmaceutical companies worldwide.

The company uses its life sciences tools revenue to fund pre-symptomatic diagnostic testing for major treatable human conditions including ovarian cancer and Parkinson’s Disease. Arrayit OvaDx for pre-symptomatic ovarian cancer monitoring and screening, is scheduled for United States Food and Drug Administration (FDA) 510(k) submission during the first half of 2014.

Arrayit expects to ship seven life sciences instruments and sixty consumable products totaling $167,000 USD from its newly-opened company headquarters in the remaining two business days of 2013.

The revenue and earnings from the $167K shipments will book in the fourth quarter of 2013. Reiterating the guidance provided during the November 15th 2013 conference call, the company expects higher net income for the fourth quarter of 2013 compared to the third quarter, and double-digit revenue growth for the full fiscal year 2013 compared to 2012.